• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to "How important is the second dose of the COVID-19 mRNA vaccine?".

作者信息

Shaker Marcus S, Phillips Elizabeth, Blumenthal Kimberly G, Abrams Elissa M, Banerji Aleena, Oppenheimer John, Vander Leek Timothy K, Mack Douglas P, Wickner Paige G, Singer Alexander G, Khan David A, Greenhawt Matthew

机构信息

Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Lebanon, NH; Geisel School of Medicine at Dartmouth, Hanover, NH.

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.

出版信息

J Allergy Clin Immunol Pract. 2021 Jun;9(6):2537-2539. doi: 10.1016/j.jaip.2021.03.016.

DOI:10.1016/j.jaip.2021.03.016
PMID:34112481
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8181594/
Abstract
摘要

相似文献

1
Reply to "How important is the second dose of the COVID-19 mRNA vaccine?".对《新冠病毒mRNA疫苗的第二剂有多重要？》的回复
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2537-2539. doi: 10.1016/j.jaip.2021.03.016.
2
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.真实世界中衰弱老年人接受延长间隔和异源 COVID-19 mRNA 疫苗接种后的血清学反应（UNCoVER）：一项前瞻性观察队列研究的中期报告。
Lancet Healthy Longev. 2022 Mar;3(3):e166-e175. doi: 10.1016/S2666-7568(22)00012-5. Epub 2022 Feb 23.
3
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.分析新加坡成年人接种 2 剂 mRNA COVID-19 或灭活 SARS-CoV-2 疫苗以及接种加强针后的 COVID-19 发病率和严重程度。
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
4
How important is the second dose of the COVID-19 mRNA vaccine?新冠病毒mRNA疫苗的第二剂有多重要？
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2537. doi: 10.1016/j.jaip.2021.02.061.
5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.BNT162b2 mRNA新冠疫苗的安全性与有效性。回复
N Engl J Med. 2021 Apr 22;384(16):1578. doi: 10.1056/NEJMc2036242. Epub 2021 Feb 17.
6
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply.BNT162b2信使核糖核酸新冠疫苗在全国大规模疫苗接种中的应用。回复
N Engl J Med. 2021 May 20;384(20):1970. doi: 10.1056/NEJMc2104281. Epub 2021 Apr 21.
7
Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose.利用单次信使 RNA 疫苗剂量增强 SARS-CoV-2 感染后的母婴体液免疫。
Am J Obstet Gynecol. 2022 Sep;227(3):486.e1-486.e10. doi: 10.1016/j.ajog.2022.04.010. Epub 2022 Apr 14.
8
On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. Reply.关于孕妇中新冠病毒mRNA疫苗安全性的初步发现。回复
N Engl J Med. 2021 Oct 14;385(16):1536. doi: 10.1056/NEJMc2113516. Epub 2021 Sep 8.
9
Accelerate Coronavirus Disease 2019 (COVID-19) Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines.通过推迟mRNA疫苗的第二剂接种来加速2019冠状病毒病（COVID-19）疫苗的推广。
Clin Infect Dis. 2021 Oct 5;73(7):1320-1321. doi: 10.1093/cid/ciab068.
10
Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.肺移植受者接种第二和第三剂 SARS-CoV-2 疫苗后的血清学发现。
Immun Inflamm Dis. 2022 Aug;10(8):e646. doi: 10.1002/iid3.646.

本文引用的文献

1
How important is the second dose of the COVID-19 mRNA vaccine?新冠病毒mRNA疫苗的第二剂有多重要？
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2537. doi: 10.1016/j.jaip.2021.02.061.
2
The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis.2021 年 COVID-19 mRNA 疫苗第二针及时接种的重要性取决于第一针提供的保护作用和后续过敏反应的风险。
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2556-2561. doi: 10.1016/j.jaip.2021.04.015. Epub 2021 Apr 20.
3
A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies.一种与新冠疫苗接种策略相关的住院、死亡和经济结果的成本效益评估：普遍接种与基于过敏风险分层接种的比较。
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2658-2668.e3. doi: 10.1016/j.jaip.2021.02.054. Epub 2021 Mar 9.
4
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2 mRNA 新冠病毒疫苗在全国大规模疫苗接种环境中的效果。
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
5
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.BNT162b2疫苗接种者中SARS-CoV-2感染和新冠肺炎的早期感染率降低情况。
Lancet. 2021 Mar 6;397(10277):875-877. doi: 10.1016/S0140-6736(21)00448-7. Epub 2021 Feb 18.
6
Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination.新冠疫苗接种的延迟第二剂与标准方案对比
N Engl J Med. 2021 Mar 4;384(9):e28. doi: 10.1056/NEJMclde2101987. Epub 2021 Feb 17.
7
The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World.2021年的新冠疫情：在全球安全接种疫苗的同时避免过敏反应风险的过度诊断
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1438-1441. doi: 10.1016/j.jaip.2021.01.022. Epub 2021 Jan 30.
8
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.美国 2020 年 12 月 21 日-2021 年 1 月 10 日期间，在接种 Moderna COVID-19 疫苗第一针后出现过敏反应（包括过敏反应）。
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129. doi: 10.15585/mmwr.mm7004e1.
9
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.美国 2020 年 12 月 14 日至 23 日：在接种第一剂辉瑞-BioNTech COVID-19 疫苗后出现过敏反应（包括过敏反应）。
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. doi: 10.15585/mmwr.mm7002e1.
10
mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach.mRNA 疫苗预防 COVID-19 疾病和报告的过敏反应：当前证据和建议方法。
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1423-1437. doi: 10.1016/j.jaip.2020.12.047. Epub 2020 Dec 31.